Healthcare >> Analyst Interviews >> January 10, 2001

Specialty Pharmaceutical Stocks: Corey Davis – Chase H&q

COREY DAVIS joined Hambrecht & Quist in 1997 covering the emerging pharmaceutical industry with an emphasis on mid-cap emerging pharma names like Alza, Forest, Shire, King, and Medicis. Mr. Davis also focuses on drug delivery and specialty firms like Emisphere and Neose. He also co-covers with Alex Zisson the big-cap pharmaceuticals such as Lilly, Schering-Plough, Merck, Pfizer, and Glaxo. Prior to joining H&Q, Mr. Davis received a PhD in Molecular Biology from Princeton University. He graduated Magna Cum Laude in 1991 with High Honors in Biology from Middlebury College, where he was elected to Phi Beta Kappa. Profile
TWST: What has been the attraction for these specialty pharma stocks,

and will that attraction continue?

Dr. Davis: It's all about growth, and over the past few years many of

these companies